Removab

RSS

Withdrawn

This medicine's authorisation has been withdrawn

catumaxomab
MedicineHumanWithdrawn

Irish is available via eTranslation, the European Commission's machine translation service.

Translate to Irish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 2 June 2017, the European Commission withdrew the marketing authorisation for Removab (catumaxomab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Neovii Biotech GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Removab was granted marketing authorisation in the EU on 20 April 2009 for treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2013. The product had not been marketed in the EU since 2014. 

The European Public Assessment Report (EPAR) for Removab is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (619.17 KB - PDF)

Amharc

español (ES) (487.88 KB - PDF)

Amharc

čeština (CS) (601.56 KB - PDF)

Amharc

dansk (DA) (487.88 KB - PDF)

Amharc

Deutsch (DE) (489.31 KB - PDF)

Amharc

eesti (ET) (499.17 KB - PDF)

Amharc

ελληνικά (EL) (632.41 KB - PDF)

Amharc

français (FR) (488.88 KB - PDF)

Amharc

italiano (IT) (488.25 KB - PDF)

Amharc

latviešu (LV) (602.02 KB - PDF)

Amharc

lietuvių (LT) (570.59 KB - PDF)

Amharc

magyar (HU) (593.2 KB - PDF)

Amharc

Malti (MT) (617.05 KB - PDF)

Amharc

Nederlands (NL) (510.15 KB - PDF)

Amharc

polski (PL) (606.08 KB - PDF)

Amharc

português (PT) (487.9 KB - PDF)

Amharc

română (RO) (569.84 KB - PDF)

Amharc

slovenčina (SK) (598.37 KB - PDF)

Amharc

slovenščina (SL) (586.62 KB - PDF)

Amharc

suomi (FI) (487.89 KB - PDF)

Amharc

svenska (SV) (489.48 KB - PDF)

Amharc

Product information

български (BG) (2.42 MB - PDF)

Amharc

español (ES) (1.42 MB - PDF)

Amharc

čeština (CS) (2.01 MB - PDF)

Amharc

dansk (DA) (1.25 MB - PDF)

Amharc

Deutsch (DE) (1.36 MB - PDF)

Amharc

eesti (ET) (1.26 MB - PDF)

Amharc

ελληνικά (EL) (2.49 MB - PDF)

Amharc

français (FR) (1.39 MB - PDF)

Amharc

hrvatski (HR) (1.35 MB - PDF)

Amharc

italiano (IT) (1.29 MB - PDF)

Amharc

latviešu (LV) (2.06 MB - PDF)

Amharc

lietuvių (LT) (1.38 MB - PDF)

Amharc

magyar (HU) (2.14 MB - PDF)

Amharc

Malti (MT) (2.08 MB - PDF)

Amharc

Nederlands (NL) (1.29 MB - PDF)

Amharc

polski (PL) (2.21 MB - PDF)

Amharc

português (PT) (1.28 MB - PDF)

Amharc

română (RO) (1.54 MB - PDF)

Amharc

slovenčina (SK) (2.05 MB - PDF)

Amharc

slovenščina (SL) (2 MB - PDF)

Amharc

suomi (FI) (1.29 MB - PDF)

Amharc

svenska (SV) (1.27 MB - PDF)

Amharc

Íslenska (IS) (1.27 MB - PDF)

Amharc

norsk (NO) (1.76 MB - PDF)

Amharc
Latest procedure affecting product information:IAIN/0020
02/06/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (520.46 KB - PDF)

Amharc

español (ES) (456.72 KB - PDF)

Amharc

čeština (CS) (509.49 KB - PDF)

Amharc

dansk (DA) (456.81 KB - PDF)

Amharc

Deutsch (DE) (456.81 KB - PDF)

Amharc

eesti (ET) (457.58 KB - PDF)

Amharc

ελληνικά (EL) (514.57 KB - PDF)

Amharc

français (FR) (457.33 KB - PDF)

Amharc

italiano (IT) (456.77 KB - PDF)

Amharc

latviešu (LV) (513.5 KB - PDF)

Amharc

lietuvių (LT) (496.02 KB - PDF)

Amharc

magyar (HU) (504.19 KB - PDF)

Amharc

Malti (MT) (511.71 KB - PDF)

Amharc

Nederlands (NL) (456.72 KB - PDF)

Amharc

polski (PL) (506.7 KB - PDF)

Amharc

português (PT) (456.89 KB - PDF)

Amharc

română (RO) (500.36 KB - PDF)

Amharc

slovenčina (SK) (507.38 KB - PDF)

Amharc

slovenščina (SL) (480.94 KB - PDF)

Amharc

suomi (FI) (456.66 KB - PDF)

Amharc

svenska (SV) (457.12 KB - PDF)

Amharc

Product details

Name of medicine
Removab
Active substance
catumaxomab
International non-proprietary name (INN) or common name
catumaxomab
Therapeutic area (MeSH)
  • Ascites
  • Cancer
Anatomical therapeutic chemical (ATC) code
L01XC09

Pharmacotherapeutic group

Other antineoplastic agents

Therapeutic indication

Removab is indicated for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.

Authorisation details

EMA product number
EMEA/H/C/000972
Marketing authorisation holder
Neovii Biotech GmbH

Am Haag 6-7
82166 Graefelfing
Germany

Marketing authorisation issued
20/04/2009
Withdrawal of marketing authorisation
02/06/2017
Revision
5

Assessment history

This page was last updated on

Share this page